This post was authored by Victoria DiBiaso, Associate Vice President, Head, Office of Patient Participation & Preferred Partnerships, Sanofi
Patients today aren’t just taking part in clinical trials – they are also playing an increasing role in their design and development.
This is an important step forward in the clinical trial process; as patient input helps companies better understand the perspective of those living with the disease being studied, which can ultimately help refine our study designs and operational approach to boost recruitment.
Recognizing the importance of this shift, Eye for Pharma recently engaged executives across the healthcare industry to discuss and share their perspectives on the topic of patient-centricity in clinical trials. I had the honor of participating and sharing some insight into Sanofi’s efforts to put patients at the center of everything we do.
The resulting Eye for Pharma whitepaper proposes a “new paradigm” for patient-centered clinical trials – one that infuses patients into “the heart, head and hands” of the process, drawing upon industry best practices like those from Sanofi. Following are some key excerpts from this white paper, which you can also check out here online.
Please note that this whitepaper content is being shared with permission from author Joyce Avedisian and Eye for Pharma.